JP2014532072A - 眼疾患の治療 - Google Patents

眼疾患の治療 Download PDF

Info

Publication number
JP2014532072A
JP2014532072A JP2014535978A JP2014535978A JP2014532072A JP 2014532072 A JP2014532072 A JP 2014532072A JP 2014535978 A JP2014535978 A JP 2014535978A JP 2014535978 A JP2014535978 A JP 2014535978A JP 2014532072 A JP2014532072 A JP 2014532072A
Authority
JP
Japan
Prior art keywords
hptpβ
binding agent
antibody
ecd
ecd binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014535978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532072A5 (enExample
Inventor
ケヴィン ピーターズ，
ケヴィン ピーターズ，
ロバート シャルウィッツ，
ロバート シャルウィッツ，
Original Assignee
エアピオ セラピューティックス， インコーポレイテッド
エアピオ セラピューティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアピオ セラピューティックス， インコーポレイテッド, エアピオ セラピューティックス， インコーポレイテッド filed Critical エアピオ セラピューティックス， インコーポレイテッド
Publication of JP2014532072A publication Critical patent/JP2014532072A/ja
Publication of JP2014532072A5 publication Critical patent/JP2014532072A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014535978A 2011-10-13 2012-10-15 眼疾患の治療 Withdrawn JP2014532072A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546708P 2011-10-13 2011-10-13
US61/546,708 2011-10-13
PCT/US2012/060263 WO2013056233A1 (en) 2011-10-13 2012-10-15 Treatment of ocular disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016178592A Division JP6259503B2 (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2016178593A Division JP2016210812A (ja) 2011-10-13 2016-09-13 眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2014532072A true JP2014532072A (ja) 2014-12-04
JP2014532072A5 JP2014532072A5 (enExample) 2015-12-24

Family

ID=48082580

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014535978A Withdrawn JP2014532072A (ja) 2011-10-13 2012-10-15 眼疾患の治療
JP2016178593A Withdrawn JP2016210812A (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2016178592A Active JP6259503B2 (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2018103592A Pending JP2018131466A (ja) 2011-10-13 2018-05-30 眼疾患の治療
JP2018103593A Pending JP2018131467A (ja) 2011-10-13 2018-05-30 眼疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016178593A Withdrawn JP2016210812A (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2016178592A Active JP6259503B2 (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2018103592A Pending JP2018131466A (ja) 2011-10-13 2018-05-30 眼疾患の治療
JP2018103593A Pending JP2018131467A (ja) 2011-10-13 2018-05-30 眼疾患の治療

Country Status (11)

Country Link
US (5) US8999325B2 (enExample)
EP (2) EP2766044B1 (enExample)
JP (5) JP2014532072A (enExample)
CN (2) CN107080843A (enExample)
AU (1) AU2012323849B2 (enExample)
BR (1) BR112014008759A8 (enExample)
CA (1) CA2850824C (enExample)
ES (1) ES2774972T3 (enExample)
HK (2) HK1201438A1 (enExample)
MX (1) MX347226B (enExample)
WO (1) WO2013056233A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531259A (ja) * 2016-07-20 2019-10-31 エアーピオ セラピューティクス インコーポレイテッド ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371865B1 (en) 2006-04-07 2017-07-12 Aerpio Therapeutics, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP3556367A1 (en) 2009-07-06 2019-10-23 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in the treatment of cancer or metastasis
CN102612367B (zh) 2009-11-06 2014-02-19 阿尔皮奥治疗学股份有限公司 脯氨酰羟化酶抑制剂
MX347226B (es) 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112015023753A2 (pt) 2013-03-15 2017-07-18 Aerpio Therapeutics Inc composições, formulações e métodos para o tratamento de doenças oculares
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
KR20160104009A (ko) * 2014-01-15 2016-09-02 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 성질을 갖는 Fc-영역 변이체
JP6778110B2 (ja) 2014-01-15 2020-10-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改善されたプロテインＡ結合を有するＦｃ領域バリアント
JP6549140B2 (ja) 2014-02-19 2019-07-24 エアーピオ セラピューティクス インコーポレイテッド Ｎ−ベンジル−３−ヒドロキシ−４−置換ピリジン−２−（１ｈ）−オン
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
CN106491911A (zh) * 2016-10-24 2017-03-15 严成 一种治疗脉络膜血管瘤的中药
CN113164597B (zh) 2018-09-24 2025-02-28 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
AU2020326243A1 (en) * 2019-08-06 2022-02-17 F. Hoffmann-La Roche Ag Personalized treatment of ophthalmologic diseases
CN112322719A (zh) * 2020-11-06 2021-02-05 温州医科大学 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用
KR20250010199A (ko) * 2023-07-11 2025-01-21 재단법인 아산사회복지재단 Tie2을 과발현하는 혈관내피세포를 포함하는 망막 내 혈관신생 질환 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533337A (ja) * 2006-04-07 2009-09-17 ザ プロクター アンド ギャンブル カンパニー ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ES2236634T3 (es) * 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
DE60003011T2 (de) 1999-03-26 2004-04-08 Regeneron Pharmaceuticals, Inc. Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
EP1046715A1 (en) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
DK1292335T3 (da) 2000-06-23 2007-09-17 Bayer Schering Pharma Ag Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II)
US6316109B1 (en) 2000-09-21 2001-11-13 Ppg Industries Ohio, Inc. Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
CA2461896C (en) * 2001-09-28 2012-09-18 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethylene glycol
US20030158083A1 (en) * 2002-02-08 2003-08-21 The Procter & Gamble Company Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
JPWO2004106542A1 (ja) * 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
JP2006210811A (ja) * 2005-01-31 2006-08-10 Nippon Steel Chem Co Ltd プリント配線板の製造方法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
CA2633211A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20100256147A1 (en) * 2007-04-13 2010-10-07 Hangauer Jr David G Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders
AU2008268262C1 (en) * 2007-06-26 2015-02-19 Children's Medical Center Corporation MetAP-2 inhibitor polymersomes for therapeutic administration
CN101802011A (zh) 2007-06-29 2010-08-11 先灵公司 Mdl-1应用
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
RU2014146121A (ru) * 2009-01-12 2015-06-10 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP3556367A1 (en) 2009-07-06 2019-10-23 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in the treatment of cancer or metastasis
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
KR101823924B1 (ko) 2010-10-07 2018-01-31 에르피오 세러퓨틱스 인코포레이티드 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법
MX347226B (es) 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112015023753A2 (pt) 2013-03-15 2017-07-18 Aerpio Therapeutics Inc composições, formulações e métodos para o tratamento de doenças oculares
JP7107914B2 (ja) * 2016-07-20 2022-07-27 アイポイント ファーマシューティカルズ， インコーポレイテッド ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
CN113164597B (zh) * 2018-09-24 2025-02-28 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533337A (ja) * 2006-04-07 2009-09-17 ザ プロクター アンド ギャンブル カンパニー ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURRENT DIABETES REVIEWS, vol. 6, JPN6015050156, 2010, pages 304 - 312, ISSN: 0003216671 *
JOURNAL OF CELLULAR PHYSIOLOGY, vol. 216, JPN6015050157, 2008, pages 29 - 37, ISSN: 0003216672 *
昭和医会誌, vol. 第７０巻，第１号, JPN6015050154, 2010, pages 45 - 51, ISSN: 0003216670 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531259A (ja) * 2016-07-20 2019-10-31 エアーピオ セラピューティクス インコーポレイテッド ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体
JP7107914B2 (ja) 2016-07-20 2022-07-27 アイポイント ファーマシューティカルズ， インコーポレイテッド ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体

Also Published As

Publication number Publication date
EP2766044B1 (en) 2019-12-11
US20180044432A1 (en) 2018-02-15
JP2018131466A (ja) 2018-08-23
EP3501536B1 (en) 2025-12-24
AU2012323849A1 (en) 2014-04-17
ES2774972T3 (es) 2020-07-23
AU2012323849B2 (en) 2017-04-20
EP2766044A1 (en) 2014-08-20
JP6259503B2 (ja) 2018-01-10
CN107080843A (zh) 2017-08-22
US20200231703A1 (en) 2020-07-23
WO2013056233A1 (en) 2013-04-18
CN104066448A (zh) 2014-09-24
JP2016210811A (ja) 2016-12-15
HK1201196A1 (en) 2015-08-28
US20150232575A1 (en) 2015-08-20
MX2014004449A (es) 2014-11-10
EP3501536A1 (en) 2019-06-26
CA2850824C (en) 2023-01-03
NZ623275A (en) 2016-05-27
US20200010565A1 (en) 2020-01-09
US20130095105A1 (en) 2013-04-18
US10329357B2 (en) 2019-06-25
HK1201438A1 (en) 2015-09-04
BR112014008759A2 (pt) 2017-06-13
MX347226B (es) 2017-04-19
JP2016210812A (ja) 2016-12-15
EP2766044A4 (en) 2015-06-10
JP2018131467A (ja) 2018-08-23
CA2850824A1 (en) 2013-04-18
US8999325B2 (en) 2015-04-07
BR112014008759A8 (pt) 2017-09-12

Similar Documents

Publication Publication Date Title
JP6259503B2 (ja) 眼疾患の治療
JP6796184B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
US12145986B2 (en) Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)
AU2011224224B2 (en) Humanized and chimeric anti-properdin antibodies
NZ623275B2 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151030

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20151030

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20151118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160913

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160921

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20161013

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161021